Cagrisema Novo Nordisk

Novo Nordisk Stock Rises

Novo Nordisk upgraded at UBS as analysts call CagriSema sell-off "overdone"

Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and is in pole position to benefit from strong near-term demand for new weight-loss drugs, according to analysts at UBS.

Business Insider · 1d

Novo Nordisk upgraded to Buy from Neutral at UBS, as CagriSema selloff overdone

UBS analyst upgraded Novo Nordisk (NVO) to Buy from Neutral with a price target of DKK 750, down from DKK 1,100. Novo Nordisk is “well placed”

Investopedia on MSN · 1d

Novo Nordisk Stock Rises as UBS Upgrades Ozempic Maker, Calls Sell-Off 'Overdone'

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock to "buy" from "neutral," calling the recent sell-off of the stock "overdone.

Novo Nordisk Expands AI Partnership With Valo Health

U.S. News & World Report · 1d

Novo Nordisk Expands AI Partnership With Valo Health for Development of Obesity Drugs

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for cardiometabolic diseases using human data and artificial intelligence (AI).

Reuters · 20d

Novo Nordisk's dosing in CagriSema obesity drug trial puzzles investors

Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of its next-generation obesity drug candidate CagriSema did not reach the highest dose strength of the medicine.

Business Insider · 1d

Novo Nordisk, Valo Health expand drug discovery collaboration

Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, ty

1don MSN

Novo Nordisk Needs Answers to These 5 Key Questions

Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental ...

GlobalData on MSN20d

Novo Nordisk takes a hit as CagriSema underperforms in weight loss

Danish mega-company Novo Nordisk has taken a hit after its newest experimental weight loss drug, CagriSema, fell short ...

20don MSN

Novo Nordisk stock price takes a tumble after the Wegovy maker’s next-generation weight-loss drug underwhelms

CagriSema, a drug that Novo had hoped would become the next generation weight-loss aid, failed to meet expectations in ...

CNN20d

An experimental drug drove people to lose 23% of their body weight. It’s still seen as a disappointment

Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective ...

14d

Down 19% in 1 Day, Is Novo Nordisk Stock Still a Buy?

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO 0.15%) stock crashed ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results